VIDEO: Phase 1 HELIOS trial of Axpaxli shows ‘compelling’ results
Click Here to Manage Email Alerts
PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Dilsher S. Dhoot, MD, of California Retina Consultants, discusses positive 40-week data from the phase 1 HELIOS trial.
Patients with moderate to severe nonproliferative diabetic retinopathy received either Axpaxli (axitinib intravitreal implant, Ocular Therapeutix) or sham, with safety serving as the study’s primary endpoint.
“We saw that Axpaxli was generally well tolerated. We saw no inflammation, vasculitis or endophthalmitis,” Dhoot said.
He added that 46.2% of patients in the treatment group had either a one- or two-step improvement compared with no patients in the sham group having any improvement, which he described as “compelling data.”
Collapse
Dhoot D. Learnings from the phase 1 Axpaxli HEALIOS diabetic retinopathy study. Presented at: Clinical Trials at the Summit; June 8, 2024; Park City, Utah.
Read more about
Click Here to Manage Email Alerts